Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

pr_newswire_finance · 2026-08-21 · Bullish AI sentiment

$ADC

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of...

Read the original at pr_newswire_finance ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.